News | News By Subject | News by Disease News By Date | Search News

Hepatitis-B News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Reeling From GlobeImmune (GBIM) Hepatitis B Termination, Gilead (GILD) Faces Merck & Co. (MRK), GlaxoSmithKline (GSK) Competition     11/22/2016
Bay Area's Dynavax (DVAX) Plunges After the FDA Spurns HEPLISAV-B Again     11/14/2016
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it     11/2/2016
Bay Area's Dynavax (DVAX) Plummeted After the FDA Cancels Advisory Meeting     9/6/2016
Roche (RHHBY) Terminates Deal with Inovio Pharma (INO), Inovio to Develop Hep B Immunotherapy Solo     8/3/2016
Dynavax (DVAX)'s Possible Hep B Win Could Prove a Threat to GlaxoSmithKline (GSK)     5/3/2016
FDA Pushes Back PDUFA Date for Dynavax (DVAX)'s Hep B Vaccine HEPLISAV-B     4/27/2016
Gilead (GILD)'s Hep B Candidate Delivers in Two Late-Stage Studies     4/15/2016
Alnylam (ALNY)’s John Maraganore Provides Leadership for RNAi Development and Biotech Industry     4/4/2016
ContraVir's CMX157 Bests Gilead (GILD)'s Tenofovir AF (TAF) Against Hep B Virus in Head-to-Head In-Vitro Study     3/29/2016
Benitec (BLT.AX)'s Hepatitis B Therapy Reduces HBV DNA By 98.5% in Early Study     3/8/2016
Dynavax (DVAX) Surges as Hep B Vaccine Meets Goals in Phase III Study     1/7/2016
Tekmira (TKMR) Changes Name to Arbutus Biopharma, Kills Ebola Program and Focuses on Hepatitis B     7/22/2015
Gilead (GILD)’s Hep B Trial Failure Will Inspire M&A Activity, Say Analysts     5/29/2015
Gilead (GILD), GlobeImmune (GBIM)'s Hep B Drug Flunks Phase II Study     5/27/2015

News from Around the Web
Some Vaccines Tied to Lower Kids' Leukemia Risk, Baylor College of Medicine Study     2/3/2011
Focusing HIV Treatment Helps Control Concurrent Hepatitis B Infection, Wake Forest University School of Medicine Study     7/15/2009
Experts Identify Mutant Genes Linked To Hepatitis B, University of Tokyo Study     4/7/2009
Hepatitis B Vaccine Protection May Wane In Teens, Centers for Disease Control and Prevention (CDC) Study     10/24/2008
Hepatitis B Vaccine Not Associated with Multiple Sclerosis, University of Paris Study     9/30/2008
Researchers at The Wistar Institute Invigorate 'Exhausted' Immune Cells     9/19/2008
Hepatitis B Genotypes And Mutants May Influence Liver Cancer Risk, Journal of the National Cancer Institute     8/15/2008
Structure of Hepatitis B Mapped by Spraying Virus in Utrecht University Study     7/29/2008
FDA Seeks New Hepatitis Blood Donation Rules     5/21/2008
Hepatitis B Virus Triggers Cell 'Suicide' In Patients With Chronic Infection, University College London Study     4/9/2008
New Drug Found Better at Suppressing Hep B Virus     1/3/2008
Stanford University School of Medicine Researchers Find Way to Fight Treacherous Hepatitis B     10/2/2007
Korean Mummies May Provide Clues to Combat Hepatitis B, Hebrew University of Jerusalem Study     7/25/2007
Hepatitis B Drug Can Compromise HIV Treatment     6/21/2007
Sweat May Pass on Hepatitis B in Contact Sports     3/1/2007

Press Releases
ContraVir's Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway In Hepatitis B     12/8/2016
Health Canada Release: Information Update - Direct-Acting Antivirals, Used For Hepatitis C, May Reactivate Hepatitis B     12/2/2016
AiCuris Announces U.S. NIH Support Of Preclinical Study With AIC649 Against Chronic Hepatitis B     11/23/2016
YiSheng BioPharma Announces Completion Of Phase I Clinical Study Of A Novel Hepatitis B Vaccine With PIKA Adjuvant     11/21/2016
REPLICor Inc. Discloses Late Breaking HBV And Follow-Up HBV / HDV Clinical Data At AASLD 2016     11/15/2016
American Association for Study of Liver Diseases Release: Number Of Hepatitis B-Related Liver Transplants Drops While Hepatitis B-Related Liver Cancer Continues To Rise     11/14/2016
European CHMP Adopts Positive Opinion For Gilead (GILD)’s Vemlidy (Tenofovir Alafenamide, TAF) For The Treatment Of Chronic Hepatitis B Virus Infection     11/11/2016
FDA Approves Gilead (GILD)’s Vemlidy (Tenofovir Alafenamide) For The Treatment Of Chronic Hepatitis B Virus Infection     11/10/2016
Assembly Biosciences Initiates Phase I Clinical Program Of ABI-H0731 For Treatment Of Chronic Hepatitis B Virus Infection     11/9/2016
ContraVir Release: CMX157 Advances Head-To-Head Phase 2a Clinical Study In Hepatitis B Patients With Favorable Recommendation From DSMB     10/17/2016
First Patient Randomized In Multiple Dose Cohort Of Phase 1/1b Trial With TRANSGENE (ENX:TNG)'s TG1050 In Chronic Hepatitis B Patients     10/17/2016
ContraVir Release: CMX157 Demonstrates 99% Viral Load Reduction In Ongoing Head-To-Head Phase 2a Clinical Study Vs. Viread In Hepatitis B Patients     10/13/2016
Arrowhead Pharma (ARWR) And Spring Bank Pharmaceuticals, Inc. Announce Clinical Collaboration For ARC-520 And SB 9200 In Chronic Hepatitis B     10/6/2016
Arbutus Biopharma (ABUS) Reports Interim Multi-Dose Results From Phase II Clinical Trial Of ARB-1467 In Patients With Chronic HBV Infection     9/30/2016
ContraVir Reports New CRV431 Data Highlighting Synergistic Activity With CMX157 Against Hepatitis B     9/12/2016

//-->